Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oral Proteins and Peptides Market Snapshot
Chapter 4. Global Oral Proteins and Peptides Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Oral Proteins and Peptides Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Oral Proteins and Peptides Industry Trends
Chapter 5. Oral Proteins and Peptides Market Segmentation 1: By Type of Target Disease Indication, Estimates & Trend Analysis
5.1. Market Share by Type of Target Disease Indication, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Target Disease Indication:
5.2.1. Acromegaly
5.2.2. Celiac Disease
5.2.3. Chronic Idiopathic Constipation
5.2.4. Enteric Hyperoxaluria
5.2.5. Inflammatory Bowel Disease
5.2.6. Type II Diabetes
Chapter 6. Oral Proteins and Peptides Market Segmentation 2: By Type of Molecule, Estimates & Trend Analysis
6.1. Market Share by Type of Molecule, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Molecules:
6.2.1. Protein
6.2.2. Peptide
Chapter 7. Oral Proteins and Peptides Market Segmentation 3: By Type of Biological Target, Estimates & Trend Analysis
7.1. Market Share by Type of Biological Target, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Biological Targets:
7.2.1. GC-C
7.2.2. Insulin Receptor
7.2.3. Oxalate
7.2.4. Others
Chapter 8. Oral Proteins and Peptides Market Segmentation 4: By Type of Mechanism of Action, Estimates & Trend Analysis
8.1. Market Share by Type of Mechanism of Action, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Mechanism of Action:
8.2.1. Receptor Stimulation
8.2.2. Substrate Degradation
8.2.3. Others
Chapter 9. Oral Proteins and Peptides Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Oral Proteins and Peptides Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Target Disease Indication, 2024-2031
9.2.3. North America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2024-2031
9.2.4. North America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Biological Target, 2024-2031
9.2.5. North America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Mechanism of Action, 2024-2031
9.3. Europe
9.3.1. Europe Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Target Disease Indication, 2024-2031
9.3.3. Europe Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2024-2031
9.3.4. Europe Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Biological Target, 2024-2031
9.3.5. Europe Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Mechanism of Action, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Target Disease Indication, 2024-2031
9.4.3. Asia Pacific Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2024-2031
9.4.4. Asia Pacific Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts By Type of Biological Target, 2024-2031
9.4.5. Asia Pacific Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Mechanism of Action, 2024-2031
9.5. Latin America
9.5.1. Latin America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Target Disease Indication, 2024-2031
9.5.3. Latin America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2024-2031
9.5.4. Latin America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Biological Target, 2024-2031
9.5.5. Latin America Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Mechanism of Action, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Target Disease Indication, 2024-2031
9.6.3. Middle East & Africa Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2024-2031
9.6.4. Middle East & Africa Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Biological Target, 2024-2031
9.6.5. Middle East & Africa Oral Proteins and Peptides Market Revenue (US$ Million) Estimates and Forecasts by Type of Mechanism of Action, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. . AstraZeneca
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerType of Target Disease Indicationance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Biocon Chiasma
10.2.3. Generex Biotechnology
10.2.4. Novo Nordisk A/S
10.2.5. Allergan
10.2.6. Oramed Pharmaceuticals
10.2.7. Proxima Concepts
10.2.8. Synergy Pharmaceuticals
10.2.9. Tarsa Therapeutics
10.2.10. Sanofi
10.2.11. F. Hoffmann-La Roche Ltd
10.2.12. Novo Nordisk A/S
10.2.13. Abbvie Inc.
10.2.14. Pfizer Inc.
10.2.15. Bausch Health Companies Inc.
10.2.16. Chiesi Farmaceutici S.P.A.
10.2.17. Acadia Pharmaceuticals Inc.
10.2.18. Aurinia Pharmaceuticals Inc.
10.2.19. Merck & Co., Inc.
10.2.20. Johnson & Johnson Services, Inc.
10.2.21. Swk Holdings
10.2.22. R-Pharm Jsc
10.2.23. Entera Bio Ltd.
10.2.24. Proxima Concepts
10.2.25. AstraZeneca Plc
10.2.26. Regor Therapeutics Group
10.2.27. Terns Pharmaceuticals, Inc.
10.2.28. Structure Therapeutics
10.2.29. Viking Therapeutics
10.2.30. Protagonist Therapeutics Inc.
10.2.31. Rani Therapeutics
10.2.32. Carmot Therapeutics, Inc.
10.2.33. Zealand Pharma
10.2.34. Sciwind Biosciences Co., Ltd.
10.2.35. Jiangsu Hengrui Pharmaceuticals Co., Ltd
10.2.36. Corning Incorporated
10.2.37. Other Market Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.